Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: implications for resource-limited settings?
Lawn, S.D.; Wood, R.
Journal of Infectious Diseases 194(10): 1467-8; Author Reply 1468
2006
ISSN/ISBN: 0022-1899 PMID: 17054078 DOI: 10.1086/508549Document Number: 235649
Human endogenous retroviruses (HERVs) arose in antiquity from stable integration into the human genome. The mechanism for activation of HERVs has not been fully elucidated. Toxoplasmosis, caused by Toxoplasma gondii, is a medically important parasitic infection with worldwide distribution. To search for a tentative link between toxoplasmosis and HERV activation, HERV expression profiles of human neuroepithelial SK-N-MC cells infected with T. gondii were analyzed. Increased transcriptional activity of class I, II, and III HERV elements was observed in infected cells, suggesting that T. gondii can influence the transcription of HERVs in neuronal cells.
Document emailed within 0-6 h
Related Documents
Venkatesh, K.K.; Srikrishnan, A.K.; Mayer, K.H.; Kumarasamy, N.; Raminani, S.; Thamburaj, E.; Prasad, L.; Triche, E.W.; Solomon, S.; Safren, S.A. 2010: Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings Aids Patient Care and Stds 24(12): 795-803Loubiere, S.; el Filal, K.M.; Sodqi, M.; Loundou, A.; Luchini, S.ép.; Cleary, S.; Moatti, J.-P.; Himmich, H. 2008: When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience Antiviral Therapy 13(2): 241-251
Vitoria, M.; Ford, N.; Doherty, M.; Flexner, C. 2014: Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings Antiviral Therapy 19(Suppl 3): 31-37
Kumarasamy, N.; Venkatesh, K.K.; Devaleenol, B.; Saghayam, S.; Manohar, D.; Poongulali, S.; Yepthomi, T.; Ambrose, P.; Solomon, S.; Mayer, K.H. 2010: Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting International Journal of Infectious Diseases: Ijid: Official Publication of the International Society for Infectious Diseases 13(6): E360-E364
Gallant, J.E.; Mehta, S.H.; Sugarman, J. 2013: Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 57(6): 884-887
Nachega, J B; Mills, E J 2007: Antiretroviral therapy adherence in resource-limited and resource-rich settings: current status of knowledge and research priorities Therapy 4(6): 775-786
Russo, G.; Paganotti, G.M.; Soeria-Atmadja, S.; Haverkamp, M.; Ramogola-Masire, D.; Vullo, V.; Gustafsson, L.L. 2016: Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments Infection Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 37: 192-207
Ramana, K.V.; Sabitha, V.; Rao, R. 2013: A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ Cell Counts and Disease Progression in Resource Poor Settings in Highly Active Antiretroviral Therapy (HAART) Era Journal of Clinical and Diagnostic Research: Jcdr 7(7): 1332-1335
Havers, F.P.; Detrick, B.; Cardoso, S.W.; Berendes, S.; Lama, J.R.; Sugandhavesa, P.; Mwelase, N.H.; Campbell, T.B.; Gupta, A. 2014: Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings Plos one 9(4): E95164
Walensky, R.P.; Wolf, L.L.; Wood, R.; Fofana, M.O.; Freedberg, K.A.; Martinson, N.A.; Paltiel, A.D.; Anglaret, X.; Weinstein, M.C.; Losina, E.; Messou, E.èn.; Seyler, C.; Touré, S.; Yazdanpanah, Y.; Kumarasamy, N.; Ganesh, J.; Ganesh, A.K.; Gray, G.; McIntyre, J.; Mohapi, L.; Cotich, K.; Goldie, S.; Horsburgh, C.R.; Kimmel, A.; Lipsitch, M.; McCormick, A.; Rydzak, C.; Seage, G.R.; Zhang, H.; Hsu, H.E.; Bassett, I.V.; Bender, M.A.; Chung, S.; Ciaranello, A.; Linas, B.P.; Lu, Z.; Morris, B.; Saxena, A.; Sloan, C.; Uhler, L.; Wang, B. 2009: When to start antiretroviral therapy in resource-limited settings Annals of Internal Medicine 151(3): 157-166
Ford, N.; Calmy, A. 2010: Improving first-line antiretroviral therapy in resource-limited settings Current Opinion in HIV and Aids 5(1): 38-47
Hirschhorn, L.R.; Oguda, L.; Fullem, A.; Dreesch, N.; Wilson, P. 2006: Estimating health workforce needs for antiretroviral therapy in resource-limited settings Human Resources for Health 4: 1
Prendergast, A; Cotton, M; Gibb, D M 2008: When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings? Future HIV Therapy 2(3): 201-208
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Jallow, S.; Alabi, A.; Sarge-Njie, R.; Peterson, K.; Whittle, H.; Corrah, T.; Jaye, A.; Cotten, M.; Vanham, G.; McConkey, S.J.; Rowland-Jones, S.; Janssens, W. 2009: Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants Journal of Clinical Microbiology 47(7): 2200-2208
Vitoria, M.; Vella, S.; Ford, N. 2013: Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges Current Opinion in HIV and Aids 8(1): 12-18
Sawe, F.K.; McIntyre, J.A. 2009: Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 49(3): 463-465
Sulaiman, M.M.; Shettima, J.; Ummate, I.; Arogundade, F.A.; Yusuph, H.; Nwankwo, E.; Sanusi, A.A.; Akinsola, A. 2022: Comparative Evaluation of Prevalence, Risk Factors, and Pathologic Features of Kidney Disease in Highly Active Antiretroviral Therapy-Naive and Highly Active Antiretroviral Therapy-Experienced Patients at a Tertiary Health Facility in Maiduguri, Northeastern Nigeria Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 33(1): 72-79
Baiocchi, O.C.G.; Colleoni, G.W.B.; Navajas, E.V.; Duarte, L.Claudio.C.; Alves, A.C.; Andrade, A.Lucia.S.S.; Kerbauy, J.; Oliveira, J.Salvador.R. 2002: Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma Acta Oncologica 41(2): 192-196